An interventional study of Noninvasive mechanical ventilation and Nasal high-flow oxygen therapy in Interstitial Lung Disease and Acute Respiratory Failure, sponsored by ADIR Association. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-27.
Sponsored by ADIR Association · Not applicable, Interventional, and Treatment
The objectives of this study are to compare the physiological consequences of high-flow oxygen therapy and noninvasive mechanical ventilation on ventilation, respiratory work and hemodynamics during acute respiratory failure in diffuse interstitial pneumonia.
680 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.
This study's planned enrollment of 18 is below the median of 60 across 384 interventional studies indexed under Lung Diseases, Interstitial.
Browse Lung Diseases, Interstitial studies →ADIR Association is the lead sponsor of 27 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient will be placed under noninvasive mechanical ventilation during 30 min, then continuous positive airway pressure during 30 min and then nasal high-flow oxygen during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
Device: Noninvasive mechanical ventilation · Device: Nasal high-flow oxygen therapy · Device: Continuous positive airway pressure
The patient will be placed under noninvasive mechanical ventilation during 30 min, then nasal high-flow oxygen during 30 min and then continuous positive airway pressure during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
Device: Noninvasive mechanical ventilation · Device: Nasal high-flow oxygen therapy · Device: Continuous positive airway pressure
The patient will be placed under continuous positive airway pressure during 30 min, then noninvasive mechanical ventilation during 30 min and then nasal high-flow oxygen during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
Device: Noninvasive mechanical ventilation · Device: Nasal high-flow oxygen therapy · Device: Continuous positive airway pressure
The patient will be placed under continuous positive airway pressure during 30 min, then nasal high-flow oxygen during 30 min and then noninvasive mechanical ventilation during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
Device: Noninvasive mechanical ventilation · Device: Nasal high-flow oxygen therapy · Device: Continuous positive airway pressure
The patient will be placed under nasal high-flow oxygen during 30 min, then continuous positive airway pressure during 30 min and then noninvasive mechanical ventilation during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
Device: Noninvasive mechanical ventilation · Device: Nasal high-flow oxygen therapy · Device: Continuous positive airway pressure
The patient will be placed under nasal high-flow oxygen during 30 min, then noninvasive mechanical ventilation during 30 min and then continuous positive airway pressure during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
Device: Noninvasive mechanical ventilation · Device: Nasal high-flow oxygen therapy · Device: Continuous positive airway pressure
Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.
Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.
Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
Pulmonary compliance
Comparison of global pulmonary compliance (Cglob) under noninvasive ventilation (NIV) and high-flow oxygen therapy (HFO) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance
Comparison of global pulmonary compliance (Cglob) under NIV and continuous positive airway pressure (CPAP) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance
Comparison of global pulmonary compliance (Cglob) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance
Comparison of global pulmonary compliance (Cglob) under HFO and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance
Comparison of global pulmonary compliance (Cglob) under NIV and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance
Comparison of global pulmonary compliance (Cglob) under CPAP and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume
Comparison of Tidal volume under CPAP and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume
Comparison of Tidal volume under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume
Comparison of Tidal volume under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume
Comparison of Tidal volume under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume
Comparison of Tidal volume under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume
Comparison of Tidal volume under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume
Comparison of end-expiratory lung volume under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume
Comparison of end-expiratory lung volume under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume
Comparison of end-expiratory lung volume under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume
Comparison of end-expiratory lung volume under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume
Comparison of end-expiratory lung volume under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume
Comparison of end-expiratory lung volume under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure
Comparison of transpulmonary pressure under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure
Comparison of transpulmonary pressure under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure
Comparison of transpulmonary pressure under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure
Comparison of transpulmonary pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure
Comparison of transpulmonary pressure under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure
Comparison of transpulmonary pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure
Comparison of driving pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure
Comparison of driving pressure under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure
Comparison of driving pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure
Comparison of driving pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure
Comparison of driving pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure
Comparison of driving pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index
Comparison of Global inhomogeneity index under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index
Comparison of Global inhomogeneity index under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index
Comparison of Global inhomogeneity index under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index
Comparison of Global inhomogeneity index under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index
Comparison of Global inhomogeneity index under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index
Comparison of Global inhomogeneity index under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate
Comparison of respiratory rate under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate
Comparison of respiratory rate under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate
Comparison of respiratory rate under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate
Comparison of respiratory rate under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate
Comparison of respiratory rate under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate
Comparison of respiratory rate under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time
Comparison of inspiratory time under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time
Comparison of inspiratory time under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time
Comparison of inspiratory time under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time
Comparison of inspiratory time under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time
Comparison of inspiratory time under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time
Comparison of inspiratory time under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time
Comparison of inspiratory time under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings
Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings
Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings
Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings
Comparison of oesophagal pressure variations between inspiration and expiration under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings
Comparison of oesophagal pressure variations between inspiration and expiration under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings
Comparison of oesophagal pressure variations between inspiration and expiration under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products
Comparison of transdiaphragmatic pressure time products under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products
Comparison of transdiaphragmatic pressure time products under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products
Comparison of transdiaphragmatic pressure time products under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products
Comparison of transdiaphragmatic pressure time products under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products
Comparison of transdiaphragmatic pressure time products under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products
Comparison of transdiaphragmatic pressure time products under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products
Comparison of oesophagal pressure time products under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products
Comparison of oesophagal pressure time products under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products
Comparison of oesophagal pressure time products under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products
Comparison of oesophagal pressure time products under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products
Comparison of oesophagal pressure time products under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products
Comparison of oesophagal pressure time products under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
ultrasound diaphragmatic strain.
Comparison of ultrasound diaphragmatic strain under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction
Comparison of diaphragmatic thickening fraction under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction
Comparison of diaphragmatic thickening fraction under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction
Comparison of diaphragmatic thickening fraction under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction
Comparison of diaphragmatic thickening fraction under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction
Comparison of diaphragmatic thickening fraction under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction
Comparison of diaphragmatic thickening fraction under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow
Comparison of peak inspiratory flow under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow
Comparison of peak inspiratory flow under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow
Comparison of peak inspiratory flow under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow
Comparison of peak inspiratory flow under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow
Comparison of peak inspiratory flow under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow
Comparison of peak inspiratory flow under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow
Comparison of peak expiratory flow under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow
Comparison of peak expiratory flow under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow
Comparison of peak expiratory flow under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow
Comparison of peak expiratory flow under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow
Comparison of peak expiratory flow under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow
Comparison of peak expiratory flow under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures
Comparison of Systolic arterial pressures under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures
Comparison of Systolic arterial pressures under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures
Comparison of Systolic arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures
Comparison of Systolic arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures
Comparison of Systolic arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures
Comparison of Systolic arterial pressures under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures
Comparison of Diastolic arterial pressures under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures
Comparison of Diastolic arterial pressures under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures
Comparison of Diastolic arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures
Comparison of Diastolic arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures
Comparison of Diastolic arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures
Comparison of Diastolic arterial pressures under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure
Comparison of Mean arterial pressures under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure
Comparison of Mean arterial pressures under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure
Comparison of Mean arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure
Comparison of Mean arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure
Comparison of Mean arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure
Comparison of Mean arterial pressures under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure
Comparison of systolic pulmonary arterial pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure
Comparison of systolic pulmonary arterial pressure under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure
Comparison of systolic pulmonary arterial pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure
Comparison of systolic pulmonary arterial pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure
Comparison of systolic pulmonary arterial pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure
Comparison of systolic pulmonary arterial pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion
Comparison of tricuspid annular plane systolic excursion under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion
Comparison of tricuspid annular plane systolic excursion under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion
Comparison of tricuspid annular plane systolic excursion under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion
Comparison of tricuspid annular plane systolic excursion under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion
Comparison of tricuspid annular plane systolic excursion under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion
Comparison of tricuspid annular plane systolic excursion under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain
Comparison of right ventricular strain under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain
Comparison of right ventricular strain under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain
Comparison of right ventricular strain under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain
Comparison of right ventricular strain under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain
Comparison of right ventricular strain under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain
Comparison of right ventricular strain under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction
Comparison of left ventricular ejection fraction under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction
Comparison of left ventricular ejection fraction under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction
Comparison of left ventricular ejection fraction under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction
Comparison of left ventricular ejection fraction under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction
Comparison of left ventricular ejection fraction under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction
Comparison of left ventricular ejection fraction under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio
Comparison of E/E' ratio under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio
Comparison of E/E' ratio under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio
Comparison of E/E' ratio under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio
Comparison of E/E' ratio under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio
Comparison of E/E' ratio under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio
Comparison of E/E' ratio under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure
Comparison of right auricular pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure
Comparison of right auricular pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure
Comparison of right auricular pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure
Comparison of right auricular pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure
Comparison of right auricular pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure
Comparison of right auricular pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output
Comparison of cardiac output under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output
Comparison of cardiac output under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output
Comparison of cardiac output under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output
Comparison of cardiac output under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output
Comparison of cardiac output under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output
Comparison of cardiac output under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate
Comparison of heart rate under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate
Comparison of heart rate under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate
Comparison of heart rate under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate
Comparison of heart rate under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate
Comparison of heart rate under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate
Comparison of heart rate under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry
Comparison of pulsed oxymetry under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry
Comparison of pulsed oxymetry under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry
Comparison of pulsed oxymetry under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry
Comparison of pulsed oxymetry under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry
Comparison of pulsed oxymetry under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry
Comparison of pulsed oxymetry under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure
Comparison of transcutaneous carbon dioxide pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure
Comparison of transcutaneous carbon dioxide pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure
Comparison of transcutaneous carbon dioxide pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure
Comparison of transcutaneous carbon dioxide pressure under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure
Comparison of transcutaneous carbon dioxide pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure
Comparison of transcutaneous carbon dioxide pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort
Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort
Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort
Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort
Visual comfort scale (from 0 to 10, 10 is maximal confort) under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort
Visual comfort scale (from 0 to 10, 10 is maximal confort) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort
Visual comfort scale (from 0 to 10, 10 is maximal confort) under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ADIR Association